Acarbose vs Tirzepatide
A side-by-side research comparison of Acarbose and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acarbose | Tirzepatide |
|---|---|---|
| Full name | Acarbose (Alpha-Glucosidase Inhibitor) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA-approved drug | FDA Approved |
| Mechanism | Inhibits intestinal alpha-glucosidase enzymes, slowing the breakdown of complex carbohydrates into glucose. This flattens post-prandial glucose and insulin excursions and shifts undigested carbohydrate to the colon, feeding beneficial short-chain-fatty-acid-producing bacteria. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 645.6 Da | 4,814 Da |
| Half-life | ~2 hours | 5 days (120 hours) |
| Bioavailability | Very low systemic (~2%); acts locally in the gut | High (SubQ ~80%) |
| Typical dose | 25-100 mg per meal | 2.5 mg → titrate up to 15 mg |
| Frequency | With carbohydrate-containing meals | Once weekly |
| Route | Oral tablet | Subcutaneous injection |
Acarbose reported benefits
- Flattens post-meal glucose spikes
- Improves glycemic variability
- Longevity signal (ITP data)
- Feeds beneficial gut bacteria
- Modest weight support
- Minimal systemic absorption
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.